Literature DB >> 12828856

Selection of oligonucleotide aptamers with enhanced uptake and activation of human leukemia B cells.

Christina C N Wu1, Januario E Castro, Marina Motta, Howard B Cottam, Diego Kyburz, Thomas J Kipps, Maripat Corr, Dennis A Carson.   

Abstract

The clinical use of oligonucleotide (ODN) therapeutics has been hampered by their limited ability to penetrate intact cells. To identify ODN properties that would facilitate cellular uptake, we developed a repetitive selection procedure using an ODN library containing at least 10(14) different molecules and human B lymphoma cells as a target. Natural phosphodiester single-stranded DNA ODNs (R-aptamers) were obtained after 10 rounds of selection. A common feature in the R-aptamers was guanine-rich 3' terminal sequences, and many also contained potential immunostimulatory (ISS) CpG sequence motifs. Two R-aptamers (R10-60 and D-R15-8) with the predominant shared characteristics were selected for further study on primary human chronic lymphocytic leukemia (CLL) B cells, which are well known to be difficult to transfect and activate. Flow cytometry analysis of the CLL cells demonstrated that the fluorochrome-labeled R-aptamers were internalized much more efficiently than nonselected random sequence ODN. Studies on sequence modifications indicated that efficient uptake required ODN multimerization, that was promoted by guanine-rich sequences at the 3' terminus. In addition, CLL cells that were exposed to the aggregating R-aptamers containing CpG motifs were strongly activated, as indicated by upregulation of CD40 levels as compared to cells treated with nonaggregating CpG R-aptamers. Together, these findings suggest that the sequence compositions in R-aptamers that promote multimerization and contain optimal ISS CpG motifs facilitate the delivery of ISS-ODN to CLL cells and enhance the activation of these cells.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12828856     DOI: 10.1089/104303403765701141

Source DB:  PubMed          Journal:  Hum Gene Ther        ISSN: 1043-0342            Impact factor:   5.695


  11 in total

Review 1.  Discovery and development of the G-rich oligonucleotide AS1411 as a novel treatment for cancer.

Authors:  Paula J Bates; Damian A Laber; Donald M Miller; Shelia D Thomas; John O Trent
Journal:  Exp Mol Pathol       Date:  2009-01-20       Impact factor: 3.362

2.  Engineering of targeted nanoparticles for cancer therapy using internalizing aptamers isolated by cell-uptake selection.

Authors:  Zeyu Xiao; Etgar Levy-Nissenbaum; Frank Alexis; Andrej Lupták; Benjamin A Teply; Juliana M Chan; Jinjun Shi; Elise Digga; Judy Cheng; Robert Langer; Omid C Farokhzad
Journal:  ACS Nano       Date:  2012-01-03       Impact factor: 15.881

3.  A hexanucleotide selected for increased cellular uptake in cis contains a highly active CpG-motif in human B cells and primary peripheral blood mononuclear cells.

Authors:  Miriam Mende; Anne Hopert; Winfried Wünsche; Marita Overhoff; Anke Detzer; Kirsten Börngen; Peter Schlenke; Holger Kirchner; Georg Sczakiel
Journal:  Immunology       Date:  2006-11-27       Impact factor: 7.397

4.  In vivo efficacy of a phosphodiester TLR-9 aptamer and its beneficial effect in a pulmonary anthrax infection model.

Authors:  Christina C N Wu; Mojgan Sabet; Tomoko Hayashi; Rommel Tawatao; Joshua Fierer; Dennis A Carson; Donald G Guiney; Maripat Corr
Journal:  Cell Immunol       Date:  2008-05-20       Impact factor: 4.868

5.  Functional correction in mouse models of muscular dystrophy using exon-skipping tricyclo-DNA oligomers.

Authors:  Aurélie Goyenvalle; Graziella Griffith; Arran Babbs; Samir El Andaloussi; Kariem Ezzat; Aurélie Avril; Branislav Dugovic; Rémi Chaussenot; Arnaud Ferry; Thomas Voit; Helge Amthor; Claudia Bühr; Stefan Schürch; Matthew J A Wood; Kay E Davies; Cyrille Vaillend; Christian Leumann; Luis Garcia
Journal:  Nat Med       Date:  2015-02-02       Impact factor: 53.440

Review 6.  Therapeutic Potential of Tricyclo-DNA antisense oligonucleotides.

Authors:  Aurelie Goyenvalle; Christian Leumann; Luis Garcia
Journal:  J Neuromuscul Dis       Date:  2016-05-27

Review 7.  Aptamers and Glioblastoma: Their Potential Use for Imaging and Therapeutic Applications.

Authors:  Emma M Hays; Wei Duan; Sarah Shigdar
Journal:  Int J Mol Sci       Date:  2017-11-30       Impact factor: 5.923

Review 8.  The Use of Tricyclo-DNA Oligomers for the Treatment of Genetic Disorders.

Authors:  Philippine Aupy; Lucía Echevarría; Karima Relizani; Aurélie Goyenvalle
Journal:  Biomedicines       Date:  2017-12-22

9.  Cancer-selective antiproliferative activity is a general property of some G-rich oligodeoxynucleotides.

Authors:  Enid W Choi; Lalitha V Nayak; Paula J Bates
Journal:  Nucleic Acids Res       Date:  2009-12-11       Impact factor: 16.971

10.  Cell-SELEX Technology.

Authors:  Shoji Ohuchi
Journal:  Biores Open Access       Date:  2012-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.